---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Specific populations questions"
description: "Specific populations questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Ocrevus be used during pregnancy? How long is contraception needed after the last dose of Ocrevus? Does Ocrevus cross the placenta or affect newborn B cells (MINORE study)? Can Ocrevus be used while breastfeeding (SOPRANINO study)? 4 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Specific populations questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Pregnancy and breastfeeding

<a id="ocrevus-pregnancy"></a>

### Can Ocrevus be used during pregnancy?

Applies to: Women with relapsing multiple sclerosis treated with OCREVUS before or during pregnancy or while breastfeeding

> “There are no adequate data on the developmental risk associated with use of ocrelizumab in pregnant women. There are no data on B-cell levels in human neonates following maternal exposure to ocrelizumab-containing products. However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. Ocrelizumab is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=There%20are%20no%20adequate%20data,to%20cross%20the%20placental%20barrier.)

> “Safe use of OCREVUS during pregnancy, labor, delivery, or breastfeeding has not been established”

Source: [OCREVUS: Pregnancy and Lactation Data, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/pregnancy-lactation.html#:~:text=Safe%20use%20of%20OCREVUS%20during,breastfeeding%20has%20not%20been%20established)

<a id="ocrevus-contraception"></a>

### How long is contraception needed after the last dose of Ocrevus?

> “Females of reproductive potential should use effective contraception while receiving ocrelizumab and for 6 months after the last dose of ocrelizumab. Instruct patients that if they are pregnant or plan to become pregnant while taking OCREVUS or OCREVUS ZUNOVO, they should inform their healthcare provider.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=Females%20of%20reproductive%20potential%20should,should%20inform%20their%20healthcare%20provider.)

<a id="ocrevus-minore-pregnancy-study"></a>

### Does Ocrevus cross the placenta or affect newborn B cells (MINORE study)?

Applies to: Women with relapsing multiple sclerosis treated with OCREVUS before or during pregnancy or while breastfeeding

> “MINORE prospective pharmacokinetic/pharmacodynamic study of OCREVUS in the peripartum period
> Assessing the placental transfer of OCREVUS during pregnancy<sup>1</sup>
> A global, multicenter, open-label, Phase IV study in women with RMS cared for in tertiary MS centers<sup>1,3</sup>
>
> Designed to evaluate<sup>1</sup>:
>
> Placental transfer of OCREVUS
> B-cell levels in newborns”

Source: [OCREVUS: Pregnancy and Lactation Data, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/pregnancy-lactation.html#:~:text=MINORE%20prospective%20pharmacokinetic%2Fpharmacodynamic%20study%20of,B%2Dcell%20levels%20in%20newborns)

> “This is the primary analysis. The complete safety data and vaccination data are not yet available.”

Source: [OCREVUS: Brochure, page 7, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=7)

> “17 mothers were considered to have had in utero exposure to OCREVUS
> • 0 to 3 months before LMP (n=14)
> • First trimester (up to gestational Week 13) of pregnancy (n=3)
> The remaining participants (n=18) were not considered to have had in utero exposure”

Source: [OCREVUS: Brochure, page 8, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=8)

> “ALL 35 PREGNANCIES RESULTED IN FULL-TERM LIVE BIRTHS<sup>7</sup>”

Source: [OCREVUS: Brochure, page 9, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=9)

> “PRIMARY ENDPOINT: B-CELL LEVELS IN ALL INFANTS (34/34,* 100%) WERE ABOVE THE AGE-SPECIFIC LLN AT WEEK 6<sup>†</sup>”

Source: [OCREVUS: Brochure, page 10, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=10)

> “There were 34/35 infants 
> available for serum evaluations 
> at Week 6. The woman who 
> received OCREVUS 1 month 
> and 25 days after LMP was lost 
> to follow-up at Week 6.<sup>7</sup>”

Source: [OCREVUS: Brochure, page 10, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=10)

> “OCREVUS WAS BELOW DETECTABLE LEVELS* IN >90% OF INFANTS (N=35)<sup>7</sup>”

Source: [OCREVUS: Brochure, page 12, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=12)

> “Birth: in umbilical cord serum samples (94.3%, 33/35<sup>†</sup>)
> • Week 6 of life: in infant serum (97.0%, 32/33<sup>†§</sup>)”

Source: [OCREVUS: Brochure, page 12, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=12)

> “*Below detectable is defined as less than LLQ (156 ng/mL).<sup>7</sup>”

Source: [OCREVUS: Brochure, page 12, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=12)

> “Overall, 4 infants experienced 5 SAEs, all of which resolved<sup>7</sup>”

Source: [OCREVUS: Brochure, page 14, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=14)

> “Definitive conclusions cannot be drawn based on these data, given the limited sample size
> • There are limited data on placental transfer in infants exposed to OCREVUS during pregnancy in this study
> – 3 infants were exposed to OCREVUS in the first trimester (up to gestational Week 13) of pregnancy, and none were exposed in the 2nd or 3rd trimester
> – 18/35 infants were not considered to have had in utero exposure to OCREVUS based on the timing of the LMP”

Source: [OCREVUS: Brochure, page 7, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-minore-placental-transfer-leave-behind-digital.pdf#page=7)

Note: MINORE is a single-arm, open-label study; the pregnancy page states that no comparisons can be made to other DMTs.

<a id="ocrevus-sopranino-breastfeeding"></a>

### Can Ocrevus be used while breastfeeding (SOPRANINO study)?

Applies to: Women with relapsing multiple sclerosis treated with OCREVUS before or during pregnancy or while breastfeeding

> “There are no data on the presence of ocrelizumab or hyaluronidase in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Ocrelizumab was excreted in the milk of ocrelizumab-treated monkeys. Human IgG is excreted in human milk, and the potential for absorption of ocrelizumab to lead to B-cell depletion in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ocrelizumab and any potential adverse effects on the breastfed infant from ocrelizumab or from the underlying maternal condition.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=There%20are%20no%20data%20on%20the,from%20the%20underlying%20maternal%20condition.)

> “SOPRANINO prospective pharmacokinetic/pharmacodynamic study of OCREVUS in the postpartum period
> Assessing the biologic transfer of OCREVUS during breastfeeding<sup>1</sup>
> A global, multicenter, open-label, Phase IV study in women with RMS cared for in tertiary MS centers<sup>1,2</sup>
>
> Designed to evaluate<sup>1</sup>:
>
> B-cell levels in infants exposed to OCREVUS during breastfeeding
> Pharmacokinetic parameters of OCREVUS in breast milk”

Source: [OCREVUS: Pregnancy and Lactation Data, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/pregnancy-lactation.html#:~:text=SOPRANINO%20prospective%20pharmacokinetic%2Fpharmacodynamic%20study%20of,of%20OCREVUS%20in%20breast%20milk)

> “BASELINE CHARACTERISTICS: 13 WOMEN WITH RMS ENROLLED”

Source: [OCREVUS: Brochure, page 9, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=9)

> “ADID*: 45.1 ug
> Average RID<sup>†</sup>: 0.3%
> Maximum RID: 0.8%
> Estimated ADID over 60 days after the mother’s first postpartum 
> OCR infusion<sup>1</sup>
> 9 out of 9 infants measured had serum concentrations of OCREVUS below 
> LLQ=156 ng/mL
> Results based on infant serum 30 days after their mothers’ first postpartum 
> infusion of OCREVUS
> <sup>§</sup>OCREVUS could not be measured in 4/13 infants due to: 
> Healthcare professional unable to draw blood (n=2), early 
> discontinuation (n=1), and an accidentally discarded 
> sample (n=1).”

Source: [OCREVUS: Brochure, page 11, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=11)

> “ADID is calculated as the arithmetic mean of the mother’s daily OCREVUS milk concentration (µg/ml) over 60 days post OCREVUS infusion 1 multiplied by an estimated infant milk intake of 150 ml/kg/day and based on the weight (kg) recorded at the Day 30 visit.<sup>6</sup>
> <sup>†</sup>The RID over 60 days is calculated as the ADID divided by the average maternal dosage over 60 days multiplied by 100.<sup>6</sup>”

Source: [OCREVUS: Brochure, page 11, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=11)

> “CO-PRIMARY ENDPOINT: NO INFANTS WITH AVAILABLE DATA* HAD B-CELL LEVELS BELOW LLN AT 30 DAYS AFTER THE FIRST 
> POSTPARTUM OCREVUS INFUSION (n=10/13)”

Source: [OCREVUS: Brochure, page 12, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=12)

> “10/13 infants had B-cell data 
> available for the primary analysis. 
> One mother discontinued due 
> to difficulties in breastfeeding. 
> For two infants, the mobile nurse 
> was unable to draw blood.<sup>6</sup>”

Source: [OCREVUS: Brochure, page 12, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=12)

> “Definitive conclusions cannot be drawn based on these data given the limited sample size”

Source: [OCREVUS: Brochure, page 8, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=8)

> “The partial use of infant formula along with breastmilk may confound the results”

Source: [OCREVUS: Brochure, page 11, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-sopranino-breastfeeding-leave-behind-digital.pdf#page=11)

> “Safe use of OCREVUS during pregnancy, labor, delivery, or breastfeeding has not been established”

Source: [OCREVUS: Pregnancy and Lactation Data, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/pregnancy-lactation.html#:~:text=Safe%20use%20of%20OCREVUS%20during,breastfeeding%20has%20not%20been%20established)

Note: SOPRANINO is a single-arm, open-label study.

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
